Cargando…
Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes
Background: The objective of this study was to demonstrate the pharmacokinetic and pharmacodynamic similarity among SAR341402 insulin aspart biosimilar/follow-on product, United States-sourced insulin aspart (NovoLog(®)), and European Union-sourced insulin aspart (NovoRapid(®)). Materials and Method...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104901/ https://www.ncbi.nlm.nih.gov/pubmed/31825248 http://dx.doi.org/10.1089/dia.2019.0351 |
_version_ | 1783512306286592000 |
---|---|
author | Kapitza, Christoph Nosek, Leszek Schmider, Wolfgang Teichert, Lenore Nowotny, Irene |
author_facet | Kapitza, Christoph Nosek, Leszek Schmider, Wolfgang Teichert, Lenore Nowotny, Irene |
author_sort | Kapitza, Christoph |
collection | PubMed |
description | Background: The objective of this study was to demonstrate the pharmacokinetic and pharmacodynamic similarity among SAR341402 insulin aspart biosimilar/follow-on product, United States-sourced insulin aspart (NovoLog(®)), and European Union-sourced insulin aspart (NovoRapid(®)). Materials and Methods: This was a single-center, randomized, double-blind, 3-treatment, 3-period, single-dose, crossover euglycemic study (NCT03202875) in 30 adult male subjects with type 1 diabetes (T1D). Subjects received 0.3 U/kg of each treatment under fasted conditions and underwent a 12-h euglycemic clamp technique to assess pharmacokinetic and pharmacodynamic activity for up to 12 h. Primary endpoints were area under the plasma insulin concentration–time curve from time zero to the last quantifiable concentration (INS-AUC(last)), and extrapolated to infinity (INS-AUC(inf)), maximum plasma insulin concentration (INS-C(max)), and the area under the body weight-standardized glucose infusion rate (GIR)–time curve from 0 to 12 hours (GIR-AUC(0–12h)) among the three treatments. GIR(max) was the main secondary endpoint. Results: Of the 30 subjects randomized, 29 completed all 3 treatment periods. Pharmacokinetic and pharmacodynamic profiles were similar in all groups. The extent of exposure (INS-C(max), INS-AUC(last), and INS-AUC(inf)) and glucodynamic activity (GIR-AUC(0–12h), GIR(max)) was similar among the three treatments. The corresponding 90% confidence intervals for pairwise treatment ratios were completely contained within the limits of 80%–125%. SAR341402 was well tolerated. Conclusions: The present study demonstrated similar pharmacokinetic exposure profiles and glucodynamic potency among SAR341402, NovoLog, and NovoRapid in subjects with T1D, supporting further clinical evaluation of SAR341402 as a biosimilar/follow-on product. |
format | Online Article Text |
id | pubmed-7104901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-71049012020-03-31 Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes Kapitza, Christoph Nosek, Leszek Schmider, Wolfgang Teichert, Lenore Nowotny, Irene Diabetes Technol Ther Original Articles Background: The objective of this study was to demonstrate the pharmacokinetic and pharmacodynamic similarity among SAR341402 insulin aspart biosimilar/follow-on product, United States-sourced insulin aspart (NovoLog(®)), and European Union-sourced insulin aspart (NovoRapid(®)). Materials and Methods: This was a single-center, randomized, double-blind, 3-treatment, 3-period, single-dose, crossover euglycemic study (NCT03202875) in 30 adult male subjects with type 1 diabetes (T1D). Subjects received 0.3 U/kg of each treatment under fasted conditions and underwent a 12-h euglycemic clamp technique to assess pharmacokinetic and pharmacodynamic activity for up to 12 h. Primary endpoints were area under the plasma insulin concentration–time curve from time zero to the last quantifiable concentration (INS-AUC(last)), and extrapolated to infinity (INS-AUC(inf)), maximum plasma insulin concentration (INS-C(max)), and the area under the body weight-standardized glucose infusion rate (GIR)–time curve from 0 to 12 hours (GIR-AUC(0–12h)) among the three treatments. GIR(max) was the main secondary endpoint. Results: Of the 30 subjects randomized, 29 completed all 3 treatment periods. Pharmacokinetic and pharmacodynamic profiles were similar in all groups. The extent of exposure (INS-C(max), INS-AUC(last), and INS-AUC(inf)) and glucodynamic activity (GIR-AUC(0–12h), GIR(max)) was similar among the three treatments. The corresponding 90% confidence intervals for pairwise treatment ratios were completely contained within the limits of 80%–125%. SAR341402 was well tolerated. Conclusions: The present study demonstrated similar pharmacokinetic exposure profiles and glucodynamic potency among SAR341402, NovoLog, and NovoRapid in subjects with T1D, supporting further clinical evaluation of SAR341402 as a biosimilar/follow-on product. Mary Ann Liebert, Inc., publishers 2020-04-01 2020-03-24 /pmc/articles/PMC7104901/ /pubmed/31825248 http://dx.doi.org/10.1089/dia.2019.0351 Text en © Christoph Kapitza, et al., 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Articles Kapitza, Christoph Nosek, Leszek Schmider, Wolfgang Teichert, Lenore Nowotny, Irene Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes |
title | Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes |
title_full | Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes |
title_fullStr | Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes |
title_full_unstemmed | Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes |
title_short | Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes |
title_sort | single-dose euglycemic clamp study demonstrating pharmacokinetic and pharmacodynamic similarity between sar341402 insulin aspart and us- and eu-approved versions of insulin aspart in subjects with type 1 diabetes |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104901/ https://www.ncbi.nlm.nih.gov/pubmed/31825248 http://dx.doi.org/10.1089/dia.2019.0351 |
work_keys_str_mv | AT kapitzachristoph singledoseeuglycemicclampstudydemonstratingpharmacokineticandpharmacodynamicsimilaritybetweensar341402insulinaspartandusandeuapprovedversionsofinsulinaspartinsubjectswithtype1diabetes AT nosekleszek singledoseeuglycemicclampstudydemonstratingpharmacokineticandpharmacodynamicsimilaritybetweensar341402insulinaspartandusandeuapprovedversionsofinsulinaspartinsubjectswithtype1diabetes AT schmiderwolfgang singledoseeuglycemicclampstudydemonstratingpharmacokineticandpharmacodynamicsimilaritybetweensar341402insulinaspartandusandeuapprovedversionsofinsulinaspartinsubjectswithtype1diabetes AT teichertlenore singledoseeuglycemicclampstudydemonstratingpharmacokineticandpharmacodynamicsimilaritybetweensar341402insulinaspartandusandeuapprovedversionsofinsulinaspartinsubjectswithtype1diabetes AT nowotnyirene singledoseeuglycemicclampstudydemonstratingpharmacokineticandpharmacodynamicsimilaritybetweensar341402insulinaspartandusandeuapprovedversionsofinsulinaspartinsubjectswithtype1diabetes |